Literature DB >> 23637009

Vaccination and inflammatory arthritis: overview of current vaccines and recommended uses in rheumatology.

Claudia Müller-Ladner1, Ulf Müller-Ladner.   

Abstract

Patients with autoimmune inflammatory rheumatic diseases are prone to infectious complications during the course of their disease. The underlying disease with an impaired immune system and additional different immunosuppressive medication render patients more susceptible to infections, some of which are potentially preventable with vaccination. Since it is not clear how strongly the underlying and medication-induced immunosuppression interferes with vaccination, a lot of questions remain about its indications, efficacy and safety . Due to these unresolved questions, in 2011, EULAR published general guidelines about vaccination in patients with autoimmune rheumatic diseases. These guidelines provide a basis for patient care and are also the basis of the following review article. With more available and earlier used immunosuppressive medications, a lot of questions still remain about optimal use of vaccines, the role of different medication combinations on efficacy and safety of vaccinations especially of the actual prevention of disease, the role of age, gender, disease activity and duration, and optimal revaccination schedules in this patient group. Actual studies elute the role of different medication combinations on efficacy and safety mainly addressing influenza and pneumococcal vaccination. In addition, interesting new data on basic immunological processes during TNF-α-blockade open up questions for further research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23637009     DOI: 10.1007/s11926-013-0330-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  31 in total

1.  Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.

Authors:  Meliha Crnkic Kapetanovic; Carmen Roseman; Göran Jönsson; Lennart Truedsson
Journal:  Clin Rheumatol       Date:  2011-09-29       Impact factor: 2.980

Review 2.  Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.

Authors:  Iuri Usêda Santana; Alline do Nascimento Gomes; Leomar D'Cirqueira Lyrio; Maria Fernanda Rios Grassi; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 2.980

3.  High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort.

Authors:  Lene Dreyer; Mikkel Faurschou; Mette Mogensen; Søren Jacobsen
Journal:  Arthritis Rheum       Date:  2011-10

4.  Notes from the field: severe varicella in an immunocompromised child exposed to an unvaccinated sibling with varicella--Minnesota, 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-07-20       Impact factor: 17.586

5.  Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.

Authors:  Gecilmara Salviato Pileggi; Cleonice Barbosa Sandoval de Souza; Virgínia Paes Leme Ferriani
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

6.  Are women with lupus at higher risk of HPV infection?

Authors:  E M Klumb; A C Pinto; G R Jesus; M Araujo; L Jascone; C R Gayer; F M Ribeiro; E M N Albuquerque; J M B Macedo
Journal:  Lupus       Date:  2010-07-06       Impact factor: 2.911

7.  Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study.

Authors:  Marloes W Heijstek; Pieter G M van Gageldonk; Guy A M Berbers; Nico M Wulffraat
Journal:  Ann Rheum Dis       Date:  2011-12-15       Impact factor: 19.103

8.  Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.

Authors:  Marloes W Heijstek; Gecilmara C S Pileggi; Evelien Zonneveld-Huijssoon; Wineke Armbrust; Esther P A H Hoppenreijs; Cuno S P M Uiterwaal; Wietse Kuis; Nico M Wulffraat
Journal:  Ann Rheum Dis       Date:  2007-02-06       Impact factor: 19.103

9.  Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.

Authors:  Sudha Visvanathan; Gregory F Keenan; Daniel G Baker; Arnold I Levinson; Carrie L Wagner
Journal:  J Rheumatol       Date:  2007-04-15       Impact factor: 4.666

10.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Authors:  Clifton O Bingham; R John Looney; Atul Deodhar; Neal Halsey; Maria Greenwald; Christine Codding; Benjamin Trzaskoma; Flavius Martin; Sunil Agarwal; Ariella Kelman
Journal:  Arthritis Rheum       Date:  2010-01
View more
  3 in total

Review 1.  Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners.

Authors:  Piyush Ranjan; Avinash Chakrawarty; Archana Kumari; Jitendra Kumar
Journal:  J Clin Diagn Res       Date:  2015-05-01

2.  An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions.

Authors:  Samar Al Emadi; Mohammed Hammoudeh; Mohamed Mounir; Ruediger B Mueller; Alvin F Wells; Housam Aldeen Sarakbi
Journal:  J Int Med Res       Date:  2017-03-07       Impact factor: 1.671

Review 3.  Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases.

Authors:  Ahmad AlEnizi; Khaled AlSaeid; Adel Alawadhi; Eiman Hasan; Entesar H Husain; Ahmad AlFadhli; Aqeel Ghanem; Fatemah Abutiban; Yaser Ali; Adeeba Al-Herz; Khuloud Mohammed; Waleed Alkandari; Ali Aldei; Hebah Alhajeri; Ahmad Dehrab; Sawsan Hayat
Journal:  Int J Rheumatol       Date:  2018-05-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.